Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction

Jang Hoon Lee; Myung Hwan Bae; Dong Heon Yang; Hun Sik Park; Yongkeun Cho; Won Kee Lee; Myung Ho Jeong; Young Jo Kim; Myeong Chan Cho; Chong Jin Kim; Shung Chull Chae

doi:10.3904/kjim.2014.268

Korean J Intern Med > Volume 31(2); 2016 > Article

Lee, Bae, Yang, Park, Cho, Lee, Jeong, Kim, Cho, Kim, Chae, and Korea Acute Myocardial Infarction Registry Investigators: Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction

Original Article

Cardiology

Korean J Intern Med 2016;31(2):267-276.

Published online: December 23, 2015

DOI: https://doi.org/10.3904/kjim.2014.268

Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction

Jang Hoon Lee¹, Myung Hwan Bae¹, Dong Heon Yang¹, Hun Sik Park¹, Yongkeun Cho¹, Won Kee Lee², Myung Ho Jeong³, Young Jo Kim⁴, Myeong Chan Cho⁵, Chong Jin Kim⁶, Shung Chull Chae¹; Korea Acute Myocardial Infarction Registry Investigators

¹Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea

²Department of Preventive Medicine, Kyungpook National University School of Medicine, Daegu, Korea

³Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea

⁴Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Korea

⁵Department of Internal Medicine, Chungbuk National University School of Medicine, Cheongju, Korea

⁶Department of Internal Medicine, Kyung Hee University East-West Neo Medical Center, Seoul, Korea

Correspondence to Shung Chull Chae, M.D. Department of Internal Medicine, Kyungpook National University Hospital, 130 Dongdeok-ro, Junggu, Daegu 41944, Korea Tel: +82-53-420-5527 Fax: +82-53-426-2046 E-mail: scchae@knu.ac.kr

Received September 4, 2014 Revised November 19, 2014 Accepted December 17, 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

See editorial "Angiotensin converting enzyme inhibitors remain the first treatment of choice" on page 237.

Abstract

Background/Aims:

Angiotensin II type 1 receptor blockers (ARBs) have not been adequately evaluated in patients without left ventricular (LV) dysfunction or heart failure after acute myocardial infarction (AMI).

Methods:

Between November 2005 and January 2008, 6,781 patients who were not receiving angiotensin-converting enzyme inhibitors (ACEIs) or ARBs were selected from the Korean AMI Registry. The primary endpoints were 12-month major adverse cardiac events (MACEs) including death and recurrent AMI.

Results:

Seventy percent of the patients were Killip class 1 and had a LV ejection fraction ≥ 40%. The prescription rate of ARBs was 12.2%. For each patient, a propensity score, indicating the likelihood of using ARBs during hospitalization or at discharge, was calculated using a non-parsimonious multivariable logistic regression model, and was used to match the patients 1:4, yielding 715 ARB users versus 2,860 ACEI users. The effect of ARBs on in-hospital mortality and 12-month MACE occurrence was assessed using matched logistic and Cox regression models. Compared with ACEIs, ARBs significantly reduced in-hospital mortality(1.3% vs. 3.3%; hazard ratio [HR], 0.379; 95% confidence interval [CI], 0.190 to0.756; p = 0.006) and 12-month MACE occurrence (4.6% vs. 6.9%; HR, 0.661; 95% CI, 0.457 to 0.956; p = 0.028). However, the benefit of ARBs on 12-month mortality compared with ACEIs was marginal (4.3% vs. 6.2%; HR, 0.684; 95% CI, 0.467 to 1.002; p = 0.051).

Conclusions:

Our results suggest that ARBs are not inferior to, and may actually be better than ACEIs in Korean patients with AMI.

Keywords: Angiotensin-converting enzyme inhibitors; Angiotensin II type 1 receptor blockers; Myocardial infarction; Mortality; Secondary prevention

INTRODUCTION

The use of angiotensin-converting enzyme inhibitors (ACEIs) is known to reduce myocardial infarction (MI) size and the risk for subsequent acute myocardial infarction (AMI), and to improve survival in post-MI patients with congestive heart failure and asymptomatic left ventricular (LV) systolic dysfunction [1-3]. Furthermore, the early administration of an ACEI has been shown to have additional mortality benefits in a recent clinical trial of patients with AMI [4]. According to the current guidelines, ACEIs are recommended as a standard medical therapy for secondary prevention in AMI patients, irrespective of LV function [5,6].

Angiotensin II type 1 receptor blockers (ARBs) also inhibit the renin-angiotensin system (RAS), in a manner that is different than ACEIs, via selective inhibition of the angiotensin II type 1 receptor [7]. Losartan and valsartan, both ARBs, have been proven to be “not inferior” to captopril, an ACEI, in patients with AMI and heart failure and/or LV systolic dysfunction [8-10]. However, ARBs have not been adequately compared to ACEIs in AMI patients without heart failure and/or LV dysfunction.

By using data from a large Korean Acute Myocardial Infarction Registry (KAMIR), we attempted to determine the frequency of ARB prescription as the first choice in ACEI- and ARB-naive AMI patients. We describe the characteristics of the patients for whom ARBs are prescribed, and the clinical impact of prescribing ARBs instead of ACEIs as a first choice drug.

METHODS

Study design and patient population

KAMIR is a prospective open observational multicenter on-line registry of Korean AMI patients that has been maintained through the support of the Korean Society of Circulation since November 2005. Details of the KAMIR database have been previously published [11].

Between November 2005 and January 2008, 14,871 suspected AMI patients were enrolled in KAMIR at the time of admission. Baseline clinical data were available from 12,280 patients from 39 participating hospitals. Among them, 1,284 patients (10.5%) who had already received ACEIs (n = 626) or ARBs (n = 720) before hospitalization were excluded, and 7,516 of the remaining 10,996 patients received ACEIs or ARBs during hospitalization or at discharge. Of these patients, 6,906 provided 12-month follow-up data, but 124 of these patients received both ACEIs and ARBs and were thus excluded. In total, 6,781 patients who received ACEIs (n = 5,951) or ARBs (n = 830) during hospitalization and at discharge were analyzed in this study.

AMI was diagnosed on the basis of characteristic clinical presentation, serial changes on an electrocardiogram (ECG) suggesting infarction or injury, and an increase in cardiac enzymes [12].

We analyzed baseline demographic characteristics, initial presentation, initial vital signs, ECG findings, laboratory test results, procedural data, and medications. Blood samples for baseline laboratory tests, except lipid measurement, were collected at admission or before percutaneous coronary intervention. Overnight fasting blood was also tested for lipid levels. The LV ejection fraction was determined using 2-dimensional echocardiography during the index hospitalization. In-hospital complications and their management were also recorded.

The 12-month major adverse cardiac events (MACEs) were defined as death and recurrent MI. During the follow-up period, follow-up data were obtained by reviewing medical records and interviewing patients by telephone. All data were recorded on an electronic web page-based case report form.

Statistical analyses

Data are expressed as mean ± standard deviation for continuous variables and as percentages for categorical variables. Comparisons between baseline variables were assessed with a Student t test for continuous variables and a Pearson chi-square test for categorical variables. Patients were categorized into two groups: patients receiving ACEIs, and patients receiving ARBs. Since patients were not randomly assigned to ACEIs or ARBs, 1:4 propensity score (PS) matching based on their probability of using ARBs was performed to reduce the effect of treatment-selection bias and potential confounding factors in this observational study. For each patient, a PS indicating the likelihood of using ARBs during hospitalization and at discharge was calculated using a non-parsimonious multivariable logistic regression model with covariates including baseline demographic characteristics, initial presentation, initial vital signs, ECG findings, laboratory tests results, procedural data, in-hospital complications, and medications [13]. Goodness of fit of the PS was evaluated using the c-statistic and the Hosmer-Lemeshow test. In the PS-matched cohort, the risk of each outcome was compared using Cox regression models. MACE and mortality were compared by Kaplan-Meier survival curves. For all analyses, a two-sided p < 0.05 was considered statistically significant. Statistical analysis was performed using SAS version 9.1. (SAS Institute Inc., Cary, NC, USA).

RESULTS

Baseline characteristics and use of medications before and after PS matching are shown in Tables 1 and 2, respectively. Overall, 4,241 of 6,098 patients (70%) in which both the LV ejection fraction and Killip status were available were Killip class 1 and had an LV ejection fraction ≥ 40%. Before PS matching, 12.2% of the patients were prescribed ARBs. Patients receiving ARBs were older, thinner, and more likely to have dyspnea, preinfarct angina pectoris, higher heart rate, higher Killip classes, atrial flutter/fibrillations at admission; during hospitalization, they were more likely to have hypertension, diabetes mellitus, previous congestive heart failure, LV dysfunction, higher glucose, and elevated creatinine levels. In contrast, ACEI users were more likely to be male, current smokers, and to have typical chest pain, ST-segment elevation MI, higher creatine kinase-MB levels, and ventricular tachyarrhythmias. Defibrillation/cardioversion were more frequently required among ACEIs users. Anti-platelet agents, except for aspirin and B-blockers, were more frequently prescribed for ACEI users, whereas diuretics were more frequently prescribed for ARB users. The GRACE (Global Registry of Acute Coronary Event) risk score was significantly higher for ARB users compared with ACEI users before PS matching (112.7 vs. 108.1, p < 0.001). The GRACE risk score model distinguished low-risk (n = 4,361, 64.3%), intermediate-risk (n = 1,873, 27.6%), and high-risk (n = 547, 8.1%) categories of patients. ARBs were used more commonly among intermediate- or high-risk patients, whereas ACEIs were used more commonly among low-risk patients (p for trend < 0.001).

After PS matching, the mean age of the 3,575 PS-matched patients was 65.7 ± 12.3 years old, and 2,439 (68.2%) were men. All baseline covariates between ACEI and ARB users were balanced after PS matching. There was no significant difference in GRACE risk score between ARB and ACEIs users (111.2 vs. 110.6, p = 0.623). There were no significant differences in use of ARBs or ACEIs across risk groups (p for trend = 0.718).

During follow-up, 229 MACEs (6.4%) including 209 deaths (5.8%) and 24 recurrent MIs (0.7%) occurred in the matched cohort (Table 3). In the logistic regression model, the in-hospital mortality was significantly lower among ARB users as compared to ACEI users (1.3% vs. 3.3%; odds ratio [OR], 0.379; 95% confidence interval [CI], 0.190 to 0.756; p = 0.006). In the Cox proportional-hazards model, there were no significant differences between ARB and ACEI users in the 12-month MACE rates (3.4% vs. 3.7%; hazard ratio [HR], 0.911; 95% CI, 0.584 to 1.420; p = 0.680) or mortality (3.1% vs. 3.1%; HR, 1.012; 95% CI, 0.633 to 1.617; p = 0.960) among hospital survivors. The 12-month MACE occurrence was significantly lower in ARB users compared with ACEI users (4.6% vs. 6.9%; HR, 0.661; 95% CI, 0.457 to 0.956; p = 0.028). The difference between 12-month mortality rates among ARB (4.3%) and ACEI (6.2%) users was marginal (HR, 0.684; 95% CI, 0.467 to 1.002; p = 0.051). Kaplan-Meier survival estimates for 12-month MACE and mortality in the matched cohort are displayed in Fig. 1. The rate of 12-month MACE increased significantly in ACEI users subsequent to the acute phase of AMI during hospitalization. Among hospital survivors, there was no significant difference in 12-month MACE between ARB users and ACEI users. The examination of subgroups showed no heterogeneity in the effect of treatment on the risk for 12-month MACE and mortality (Fig. 2).

DISCUSSION

In this multicenter observational study, the main findings were that ARBs were commonly used as the first therapy in AMI patients, particularly in those with high-risk features, and that ARB users had significantly lower in-hospital mortality and 12-month MACEs compared with ACEI users after PS matching.

The ARBs, theoretically, might be more efficacious than ACEIs at blocking RAS. In AMI patients with heart failure and/or LV dysfunction, the efficacy of ARBs compared to ACEIs for secondary prevention of MACEs has been tested in two large-scale randomized clinical studies (RCTs): OPTIMAAL (Optimal Trial in Myocardial Infarction with Angiotensin II antagonist Losartan) and VALIANT (Valsartan in Acute Myocardial Infarction Trial) [8,10]. In OPTIMAAL, losartan was associated with a significant increase in cardiovascular mortality compared to captopril. In VALIANT, valsartan was “non-inferior” to captopril in patients with high risk for MACE after AMI. Neither of these studies revealed any statistically significant difference in the primary end-points between patients treated with ACEIs and those treated with ARBs. Therefore, ACEIs are recommended as the first choice for AMI patients with heart failure and/or LV dysfunction in the current guidelines, assigning ARBs as an alternative for ACEI-intolerant patients [5,6]. However, ARBs are commonly prescribed instead of ACEIs in post-MI patients, as shown in the REACH (Reduction of Atherothrombosis for Continued Health) registry [14]. Interestingly, ARBs were also used in our observational study as the first choice RAS blockade in AMI patients, particularly in patients with high-risk features.

In the present study, ARBs significantly reduced in-hospital mortality and 12-month MACE occurrence compared with ACEIs. The rate of 12-month MACE occurrence diverged during the very acute phase of AMI during hospitalization, a period of drug dose increase, with no further subsequent divergence. Although the better prognosis among ARB users may have been the result of chance, this study suggests that it would be worth conducting RCTs to compare ARBs and ACEIs as first choice RAS blockades in AMI patients without heart failure and/or LV dysfunction.

Our study differs from the previous RCTs in several aspects. First, KAMIR was an observational study including AMI patients irrespective of the presence of heart failure and/or LV systolic dysfunction. In clinical trials on the comparative effects of RAS blockers, AMI patients without heart failure and/or LV dysfunction were not included in sizable numbers. In the present analysis, 70% of patients did not have heart failure and/or LV systolic dysfunction. Second, dosages of ACEIs and ARBs used in observational studies like ours tend to be lower compared with those in RCTs. Recent clinical studies reported that the average dosages of ACEIs used after discharge were 50% of the effective dose determined by RCTs, with no significant differences in MACEs between ARBs and ACEIs at the dosages used [15]. Therefore, the discrepancy in clinical outcomes between previous RCTs and our registry might be due to dosage differences. In this regard, registry data better reflect the clinical efficacy of ACEIs and ARBs in real-world practice. Third, methodological differences may have contributed to observed differences. In the present study, we excluded patients who had already received ACEIs or ARBs before hospitalization, whereas in VALIANT, 39.4% of the valsartan group and 38.5% of the captopril group received non-study ACEIs for an average of 5 days after the AMI, but before randomization [10]. ACEIs are known to reduce mortality in the early post-MI period, with 85% of the benefit in the first week [16]. Therefore, the early use of non-study ACEIs in VALIANT may have influenced the results. The mortality rates of ACEI-naive patients compared with those who received pre-randomization ACEIs in VALIANT have not yet been published [9,10]. Finally, ethnic differences may also have contributed to the observed differences. The prescription rate of ARBs is lower in Western countries than it is in Asia [14,17]. East Asians are more susceptible to the adverse side effect of coughing caused by ACEIs [18,19], which may have led to a relatively rapid switch from ACEIs to ARBs in East Asia. However, whether the drug response differences are solely the result of genetic differences between Asians and Westerners is still unknown. Furthermore, it is not known whether these differences cause different clinical outcomes for Asian post-MI patients.

Our study has several potential limitations. First, KAMIR was an observational study as previously explained. Although propensity analysis was performed for a large number of confounding factors, no firm conclusion can be made about the causal relationship between ACEIs or ABRs and clinical outcomes. Second, we were unable to clarify the reasons for nonprescription of ACEIs or ARBs. In addition, the details regarding dosages and specific class of ACEIs or ARBs and the timing of use of ACEIs or ARBs after the onset of MI were not obtained from the patients or their physicians. Finally, patients who had previously experienced adverse reactions to ACEIs or ARBs might have been included in our study. Considering this, we may have underestimated the prescription rates for ACEIs or ARBs. Finally, no data were available on compliance or adherence regarding ACEIs or ARBs throughout the follow-up period. We were unable to detect how much crossover occurred between ACEI-users and ARB-users.

In conclusion, ARBs significantly reduced in-hospital mortality and 12-month MACEs compared with ACEIs in Korean AMI patients. Further RCTs are required for AMI patients without heart failure and/or LV dysfunction.

KEY MESSAGE

1. Angiotensin II type 1 receptor blockers (ARBs) were commonly used in Korean acute myocardial infarction patients, particularly those with high-risk features, as a first choice therapy.

2. Korean ARB users had signif icantly lower in-hospital mortality and 12-month major adverse cardiac event occurrence compared with angiotensin-converting enzyme inhibitor users after propensity score matching.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

Korean Acute Myocardial Infarction Registry Investigators: Bon-Kwon Koo, Byung-Ok Kim, Chong-Jin Kim, Chong-Yun Rhim, Dong-Hoon Choi, Dong-Kyu Jin, Doo-Il Kim, Hyeon-Cheol Gwon, In-Ho Chae, In-Whan Seong, Jae-Young Rhew, Jang-Ho Bae, Jei-Keon Chae, Jeong-Gwan Cho, Jin-Man Cho, Jin-Yong Hwang, Jong-Hyun Kim, Jong-Seon Park, Jung-Han Yoon, Ju-Young Yang, Kee-Sik Kim, Keum-Soo Park, Ki-Bae Seung, Kyoo-Rok Han, Kyoung-Tae Jeong, Moo-Hyun Kim, Myeong-Chan Cho, Myung-Ho Jeong, Myoung-Yong Lee, Nae-Hee Lee, Seok-Kyu Oh, Seong-Wook Park, Seong-Woon Rha, Seung-Ho Hur, Seung-Jae Joo, Seung-Jea Tahk, Seung-Jung Park, Shung-Chull Chae, Soo-Joong Kim, Tae-Hoon Ahn, Taek-Jong Hong, Yang-Soo Jang, Young-Jo Kim, Young-Keun Ahn, Young-Youp Koh, and Wook-Sung Chung.

Figure 1.

Kaplan-Meier estimates of the rate of 12-month major adverse cardiac events (A) and mortality (B) associated with the use of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers.

Figure 2.

Hazard ratios and 95% confidence intervals for 12-month major adverse cardiac events occurrence (A) and mortality (B). ARBs, angiotensin II type 1 receptor blockers; ACEIs, angiotensin-converting enzyme inhibitors.

Table 1.

Baseline characteristics associated with the use of angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers before and after propensity score matching

Characteristic	Before PS match			After PS match
Characteristic	ACEIs alone (n = 5,951)	ARBs alone (n = 830)	p value	ACEIs alone (n = 2,860)	ARBs alone (n = 715)	p value
Demographic
Age, yr	64.5 ± 12.6	66.2 ± 12.3	< 0.001	65.7 ± 12.3	65.8 ± 12.3	0.855
Male sex	4,357 (73.2)	543 (65.4)	< 0.001	1,951 (68.2)	488 (68.3)	0.986
Height, cm	163.9 ± 8.7	162.7 ± 9.3	0.001	163.0 ± 8.8	163.0 ± 9.2	0.948
Weight, kg	64.7 ± 11.4	63.6 ± 11.4	0.008	63.9 ± 11.5	63.8 ± 11.3	0.933
Body mass index, kg/m²	24.0 ± 3.3	23.9 ± 3.1	0.383	23.9 ± 3.2	23.9 ± 3.1	0.979
Initial presentation
Pre-hospital resuscitation	96 (1.6)	15 (1.8)	0.680	48 (1.7)	14 (2.0)	0.607
Typical chest pain	4,976 (85.0)	664 (81.2)	0.005	2,332 (82.8)	588 (83.2)	0.822
Dyspnea	1,344 (23.7)	225 (28.1)	0.006	695 (25.4)	183 (26.5)	0.547
Pre-infarction angina pectoris	2,540 (43.3)	395 (47.7)	0.017	1,296 (45.8)	329 (46.1)	0.880
Systolic blood pressure, mmHg	129.8 ± 28.1	130.8 ± 29.9	0.355	130.9 ± 29.0	131.0 ± 29.4	0.932
Heart rate, beats/min	77.3 ± 19.3	79.1 ± 20.5	0.016	78.1 ± 19.5	78.5 ± 19.8	0.639
Killip class > 1	1,265 (22.2)	251 (30.9)	< 0.001	722 (26.2)	202 (29.0)	0.132
ECG on admission
ST elevation myocardial infarction	3,700 (62.2)	485 (58.4)	0.038	1,750 (61.2)	435 (60.8)	0.864
Anterior myocardial infarction	2,642 (46.8)	383 (48.2)	0.462	1,326 (48.4)	328 (47.9)	0.817
Inferior myocardial infarction	2,043 (36.2)	299 (37.6)	0.432	1,009 (36.8)	255 (37.2)	0.840
Heart rhythm on admission
Sinus rhythm	5,270 (91.6)	737 (90.4)	0.275	2,557 (91.7)	634 (90.6)	0.318
Atrial flutter/fibrillation	223 (3.9)	46 (5.6)	0.017	128 (4.6)	37 (5.3)	0.440
Ventricular tachycardia/ventricular fibrillation	28 (0.5)	3 (0.4)	0.644	11 (0.4)	3 (0.4)	0.899
Past history
Previous coronary heart disease	660 (11.1)	104 (12.6)	0.229	330 (11.6)	85 (11.9)	0.803
Hypertension^a	2,587 (44.0)	447 (54.4)	< 0.001	1,481 (52.3)	366 (51.8)	0.795
Diabetes mellitus^b	1,495 (25.5)	256 (31.3)	< 0.001	801 (28.4)	206 (29.3)	0.626
Hyperlipidemia^c	536 (10.2)	71 (9.8)	0.728	233 (9.2)	60 (9.6)	0.763
Current smoking	2,792 (47.3)	316 (38.3)	< 0.001	1,152 (40.6)	292 (41.1)	0.801
Previous congestive heart failure	77 (1.3)	18 (2.2)	0.045	40 (1.4)	13 (1.8)	0.406
Previous cerebrovascular disease	358 (6.0)	52 (6.3)	0.778	173 (6.0)	47 (6.6)	0.602
Left ventricular ejection fraction	52.0 ± 13.0	50.9 ± 13.4	0.023	51.3 ± 12.6	51.1 ± 13.1	0.754
Laboratory findings
Glucose, mg/dL	167.0 ± 76.4	174.2 ± 87.4	0.026	170.2 ± 80.5	172.6 ± 80.8	0.489
Creatinine, mg/dL	1.09 ± 0.94	1.34 ± 1.83	< 0.001	1.11 ± 0.91	1.18 ± 1.13	0.142
CK-MB, ng/mL	142.6 ± 241.4	122.6 ± 179.1	0.004	129.3 ± 169.4	129.1 ± 186.0	0.976
Total cholesterol, mg/dL	185.0 ± 44.0	186.3 ± 47.9	0.451	187.3 ± 45.4	186.3 ± 45.3	0.608
Triglyceride, mg/dL	129.2 ± 109.0	129.6 ± 82.4	0.929	133.0 ± 128.0	129.1 ± 80.4	0.448
HDL-C, mg/dL	45.6 ± 20.9	44.8 ± 22.0	0.381	45.2 ± 14.1	45.2 ± 23.1	0.962
LDL-C, mg/dL	119.4 ± 40.2	119.9 ± 43.4	0.726	120.5 ± 41.1	120.4 ± 43.4	0.952
PCI at index hospitalization	5,090 (85.5)	711 (85.7)	0.920	2,474 (86.5)	617 (86.3)	0.883
CABG at index hospitalization	84 (1.4)	14 (1.7)	0.518	44 (1.5)	10 (1.4)	0.775
In-hospital complication
Cardiogenic shock	379 (6.4)	51 (6.1)	0.804	168 (5.9)	42 (5.9)	1.000
New atrial flutter/fibrillation	43 (0.7)	14 (1.7)	0.004	28 (1.0)	6 (0.8)	0.730
Ventricular tachycardia/ventricular fibrillation during hospitalization	235 (3.9)	16 (1.9)	0.004	63 (2.2)	16 (2.2)	0.955
Heart failure	1,059 (17.8)	170 (20.5)	0.060	555 (19.4)	140 (19.6)	0.916
Acute renal failure	30 (0.5)	4 (0.5)	0.932	12 (0.4)	3 (0.4)	1.000
Cerebrovascular accidents	46 (0.8)	4 (0.5)	0.359	14 (0.5)	4 (0.6)	0.813
Major bleeding	14 (0.2)	4 (0.5)	0.196	10 (0.3)	2 (0.3)	0.772
Management of in-hospital complication
In-hospital resuscitation	160 (2.7)	17 (2.0)	0.278	58 (2.0)	14 (2.0)	0.905
Defibrillation/cardioversion	164 (2.8)	11 (1.3)	0.015	44 (1.5)	11 (1.5)	1.000
Mechanical ventilator	217 (3.6)	27 (3.3)	0.569	86 (3.0)	22 (3.1)	0.922

Values are presented as mean ± SD or number (%).

PS, propensity score; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II type 1 receptor blockers; ECG, electrocardiogram; CK-MB, creatine kinase-MB; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting.

^a Defined as previously diagnosed by a physician, receiving medication to lower blood pressure.

^b Defined as previously diagnosed by a physician, receiving medication to lower blood glucose.

^c Defined as previously diagnosed by a physician, receiving lipid lowering drugs.

Table 2.

Medications prescribed in conjunction with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers before and after propensity score matching

Variable	Before PS match			After PS match
Variable	ACEIs alone (n = 5,951)	ARBs alone (n = 830)	p value	ACEIs alone (n = 2,860)	ARBs alone (n = 715)	p value
Previous medication
Aspirin	357 (6.0)	85 (10.2)	< 0.001	231 (8.1)	62 (8.7)	0.604
Clopidogrel	95 (1.6)	25 (3.0)	0.004	57 (2.0)	18 (2.5)	0.381
β-Blocker	261 (4.4)	51 (6.1)	0.023	146 (5.1)	40 (5.6)	0.598
Lipid-lowering drug	170 (2.9)	37 (4.5)	0.012	102 (3.6)	25 (3.5)	0.928
Calcium channel blocker	399 (6.7)	89 (10.7)	< 0.001	236 (8.3)	58 (8.1)	0.903
Diuretic	152 (2.6)	30 (3.6)	0.077	92 (3.2)	23 (3.2)	1.000
Nitrate	158 (2.7)	30 (3.6)	0.115	81 (2.8)	23 (3.2)	0.584
In-hospital medications
Aspirin	5,908 (99.3)	823 (99.2)	0.703	2,836 (99.2)	709 (99.2)	1.000
Clopidogrel	5,837 (98.1)	800 (96.4)	0.001	2,787 (97.4)	694 (97.1)	0.565
β-Blocker	5,072 (85.2)	596 (71.8)	< 0.001	2,252 (78.7)	560 (78.3)	0.807
Lipid-lowering drug	4,839 (81.3)	662 (79.8)	0.283	2,315 (80.9)	583 (81.5)	0.717
Heparin	4,795 (80.6)	671 (80.8)	0.854	2,317 (81.0)	580 (81.1)	0.949
Calcium channel blocker	619 (10.4)	182 (21.9)	< 0.001	394 (13.8)	119 (16.6)	0.056
Diuretic	1,697 (28.5)	344 (41.4)	< 0.001	1,072 (37.5)	273 (38.2)	0.730
Nitrate	4,846 (81.4)	667 (80.4)	0.459	2,307 (80.7)	579 (81.0)	0.849
Discharge medication
Aspirin	5,578 (98.2)	787 (97.3)	0.066	2,684 (98.0)	683 (97.6)	0.488
Clopidogrel	5,343 (94.1)	732 (90.5)	< 0.001	2,554 (93.2)	643 (91.9)	0.200
β-Blocker	4,597 (80.9)	557 (68.9)	< 0.001	2,044 (74.6)	515(73.6)	0.568
Lipid-lowering drug	4,570 (80.5)	641 (79.2)	0.407	2,202 (80.4)	560 (80.0)	0.815
Calcium channel blocker	428 (7.5)	148 (18.3)	< 0.001	308 (11.2)	79 (11.3)	0.976
Diuretic	1,136 (20.0)	264 (32.6)	< 0.001	771 (28.1)	206 (29.4)	0.503
Nitrate	3,486 (61.4)	490 (60.6)	0.656	1,690 (61.7)	430 (61.4)	0.895

Values are presented as number (%).

PS, propensity score; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II type 1 receptor blockers.

Table 3.

Twelve-month clinical outcomes in the matched cohort

End point	ACEIs group (n = 2,860)	ARBs group (n = 715)	ARBs vs. ACEIs		ARBs vs. ACEIs
End point	ACEIs group (n = 2,860)	ARBs group (n = 715)	OR (95% CI)	p value	HR (95% CI)	p value
In-hospital	2,860	715
Death from any cause	93 (3.3)	9 (1.3)	0.379 (0.190–0.756)	0.006
Death from cardiac cause	75 (2.6)	8 (1.1)	0.420 (0.202–0.875)	0.021
Death from non-cardiac cause	18 (0.6)	1 (0.1)	0.221 (0.029–1.659)	0.142
Hospital survivors	2,767	706
Death or recurrent MI	103 (3.7)	24 (3.4)			0.911 (0.584-1.420)	0.680
Death from any cause	85 (3.1)	22 (3.1)			1.012 (0.633-1.617)	0.960
Death from cardiac cause	61 (2.2)	14 (2.0)			0.897 (0.502-1.604)	0.715
Death from non-cardiac cause	24 (0.9)	8 (1.1)			1.303 (0.585-2.901)	0.517
Recurrent MI	22 (0.8)	2 (0.3)			0.355 (0.083–1.509)	0.161
Overall	2,860	715
Death or recurrent MI	196 (6.9)	33 (4.6)			0.661 (0.457-0.956)	0.028
Death from any cause	178 (6.2)	31 (4.3)			0.684 (0.467-1.002)	0.051
Death from cardiac cause	136 (4.8)	22 (3.1)			0.636 (0.406-0.998)	0.049
Death from non-cardiac cause	42 (1.5)	9 (1.3)			0.840 (0.409-1.725)	0.634
Recurrent MI	22 (0.8)	2 (0.3)			0.355 (0.084-1.510)	0.161

Values are presented as number (%).

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker; OR, odds ratio; CI, confidence interval; HR, hazard ratio; MI, myocardial infarction.

REFERENCES

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429–1435.

2. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821–828.

3. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669–677.

4. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669–685.

5. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909–2945.

6. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology; Bassand JP, et al.; Hamm CW. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598–1660.

7. Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 2004;109:8–13.

8. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752–760.

9. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–1906.

10. McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006;47:726–733.

11. Lee JH, Park HS, Chae SC, et al. Predictors of six-month major adverse cardiac events in 30-day survivors after acute myocardial infarction (from the Korea Acute Myocardial Infarction Registry). Am J Cardiol 2009;104:182–189.

12. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000;21:1502–1513.

13. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41–55.

14. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180–189.

15. Hansen ML, Gislason GH, Kober L, et al. Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction. Br J Clin Pharmacol 2008;65:217–223.

16. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97:2202–2212.

17. Kohro T, Hayashi D, Okada Y, Yamazaki T, Nagai R, JCAD Investigators. Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study. Circ J 2007;71:1835–1840.

18. Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004;10:499–509.

19. Woo KS, Norris RM, Nicholls G. Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities). Am J Cardiol 1995;75:967–968.